NewcelX NCEL-101 / IsletRx
NewcelX
A pre-IND stem-cell-derived islet replacement program for insulin-dependent T1D, which NewcelX plans to pair with Eledon's anti-CD40L antibody tegoprubart in a calcineurin-inhibitor-free immunosuppression regimen. That is a lighter drug burden, not freedom from drugs — anti-CD40L is itself chronic systemic immunosuppression. An FDA pre-IND meeting was completed in July 2026; no IND has been filed, no trial is open, and there is no human data.
The scorecard
No human data yet; the program is pre-IND and has not entered a first-in-human trial.[2]
Durability is a stated goal, especially with tegoprubart immune modulation, but remains preclinical.[3]
Scored at the same level as zimislecel — lifelong systemic immunosuppression — because that is what is planned. Pairing NCEL-101 with anti-CD40L tegoprubart in a calcineurin-inhibitor-free protocol is a lighter immune burden, not a drug-free one: anti-CD40L is itself chronic systemic immunosuppression, and in the one islet trial where this regimen is actually running it is given on top of ATG/basiliximab, mycophenolate and etanercept. It previously scored 25, above zimislecel; we removed the premium because it rewarded an intention. This regimen exists on paper — the program is pre-IND, with no human data of any kind.[3]
As an islet replacement therapy it will require transplantation or infusion; final route is not yet publicly established.[1]
Potentially scalable if it reaches clinic, but eligibility is undefined before the IND and first protocol.[2]
Pre-IND package submitted May 2026; a successful FDA Type B pre-IND meeting followed in July 2026, with the company reporting favourable feedback on manufacturing and preclinical data — but this is still pre-IND, with no first-in-human trial open and no announced IND date.[4]
The full picture
NewcelX is not yet a clinical competitor to Vertex or Sana, but it is now visible enough to track. The May 2026 pre-IND package and Eledon collaboration put NCEL-101 on the horizon for first-in-human testing. The scientific bet is familiar: manufacture insulin-producing islet cells, then pair them with immune modulation strong enough to protect the graft without the worst transplant-drug burden.
Where it stands, July 2026
NewcelX announced on 1 July 2026 that it had completed a Type B pre-IND meeting with the FDA.1 According to the company, the agency gave favourable feedback on its manufacturing (CMC) processes and its preclinical package, and there was alignment on the proposed development strategy — clearing NewcelX to move on to IND-enabling work. That is a real step forward from a package merely being submitted, but it is worth being precise about what it is not: no Investigational New Drug application has been filed, no trial-start date has been announced, and no human has yet received NCEL-101.
Note also that the FDA does not publish pre-IND meeting outcomes, so everything we know about how that meeting went comes from NewcelX's own press release. The fact that the meeting happened is solid; the adjective "successful" is the company's.
NewcelX describes NCEL-101 as an enriched stem-cell-derived islet product — the company says roughly 60% of the beta cells co-express insulin and NKX6.1, and that 99.98% of the product is of endocrine lineage.1 These are manufacturer figures from a press release, not independently verified or peer-reviewed data. The plan remains to pair the cells with Eledon's anti-CD40L antibody tegoprubart in a calcineurin-inhibitor-free immunosuppressive regimen — a lighter immune burden than the standard transplant drug cocktail, but still immunosuppression, not freedom from it.
References
-
NewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 Diabetes — NewcelX press release, 1 July 2026. ↩ ↩2
Coming soon
ETA · FDA Type B pre-IND meeting completed (July 2026); IND-enabling work under way, with no IND filing or trial-start date announced
Sources
- [1]NewcelX pipeline: IsletRx / NCEL-101 for type 1 diabetes · manufacturer
- [2]NewcelX submits pre-IND package to FDA for NCEL-101 for type 1 diabetes · manufacturer · 2026-05-27
- [3]NewcelX announces strategic collaboration with Eledon to advance NCEL-101 program for type 1 diabetes · manufacturer · 2026-03-09
- [4]NewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 Diabetes · manufacturer · 2026-07-01 — Company press release. The FDA does not publish pre-IND meeting outcomes, so the characterisation of the feedback and the cell-purity figures are manufacturer claims.